Navigation Links
Salt Takes Center Stage in Chicken Producer's New Consumer Campaign
Date:3/30/2009

West Coast-based Foster Farms Reaffirms Commitment to Never Injecting Its Fresh Chicken with Saltwater

LIVINGSTON, Calif., March 30 /PRNewswire/ -- As leaders from the medical, health and food industries gather today at an Institute of Medicine meeting to explore strategies to reduce sodium in the American diet, West Coast poultry company Foster Farms readies an awareness campaign highlighting its natural, fresh chicken and reassuring consumers that the family-owned poultry company has never, and will never, inject its fresh chicken with saltwater.

Beginning in April, the company will launch a consumer awareness campaign to inform shoppers of the little known practice of some producers "plumping" - or injecting - fresh chicken with unusable saltwater. "Plumping" costs consumers in their health and their bottom line. The average serving of plumped chicken contains more sodium than a large order of French fries or more than 25% of the daily recommended allowance. Research shows that high sodium intake is linked to many diseases, including high blood pressure and heart disease(1). Consumers who purchase plumped chicken could pay up to $1.50 per package, or more than $100 per year per household(2), on saltwater, alone.

Some chicken companies have been plumping chicken for years and labeling the product "Natural." "There's nothing 'natural' about saltwater that consumers are unknowingly paying for at chicken prices," said Ira Brill, Director of Marketing and Advertising Services for Foster Farms. "We believe consumers who purchase fresh chicken should get what they expect to pay for, particularly in these tough economic times. We feel it's important to continue our 70-year commitment to producing premium, all natural, fresh poultry."

Foster Farms' new program, which involves television advertising, events, online and out-of-home components, begins April 13 and will focus on uncovering the p
'/>"/>

SOURCE Foster Farms
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. P&G Takes Bold Step and Adjusts Sustainability Goals
2. Electrical Signal in Brain Seems to Warn of Mistakes
3. Patient Guide Series Takes the Gibberish Out of Medicine
4. Obesity Takes Years Off Your Life
5. U.S. Secretary of Labor Hilda L. Solis takes action to prevent workers exposure to food flavorings chemical
6. Bust Your Dust Without Lifting a Finger: Enter the Nobody Outcleans The Maids Sweepstakes
7. The Detroit Medical Center Pioneers New EMR System Preventing Medication Mistakes
8. Global War on Drugs Takes Devastating Toll on Human Lives, Advocates Say
9. Dr. V. Takes Health Education to a New Level
10. Sandal Evolution(R) Takes a Healthy Step
11. Virtua Health Takes Next Step for Continuing Hospital Construction
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Autism Speaks Applauds Supreme Court Decision Upholding Families' Right to Challenge IEPs Without First Trying Out School District Proposed Placement 2Health News:Autism Speaks Applauds Supreme Court Decision Upholding Families' Right to Challenge IEPs Without First Trying Out School District Proposed Placement 3Health News:Mouse mammary tumor virus can replicate in human cells 2Health News:Health IT Now! Coalition Applauds Representatives Eshoo and Rogers for Introducing Health IT Legislation 2Health News:Salmonella Outbreak Traced to Banquet and Store Brand Frozen Pot Pies 2Health News:PRI Criticizes Guttmacher Report 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 2Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 3Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 4Health News:Study reveals how stem cells decide to become either skeletal or smooth muscle 5
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 1Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 2Ser Padres Joins Forces with la Doctora Alizas VidaySalud com to Offer the Hispanic Community Unprecedented Online Health Related Content in Spanish 49632 3Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 1Transcend Medical Raises 2435 Million Series B Round Towards Development of Novel Glaucoma Treatment 49630 2DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 1DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture 28EDC 29 Clinical Trial Survey 4626 2
Other Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures 2